A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

NCT06546280 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
38
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Zhujiang Hospital